Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 dopamine receptors

ChemMedChem

Volumn 4, Issue 9, 2009, Pages 1514-1522

  Vendrell, Marc ^a,b   Soriano, Aroa ^a   Casadó, Vicent ^a   Díaz, José Luis ^a   Lavilla, Rodolfo ^a   Canela, Enric I ^a   Lluís, Carme ^a   Franco, Rafael ^a   Albericio, Fernando ^a   Royo, Miriam ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

Combinatorial chemistry; GPCRs; Indolo 2,3 a quinolizidines; Parkinson's disease; Receptors

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CYCLIC AMP; DIHYDROPYRIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; INDOLOQUINOLIZIDINE; LEVODOPA; LIGAND; PEPTIDE; PYRIDINIUM DERIVATIVE; RADIOLIGAND; TETRACYCLINE; TRYPTOLINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; CHROMATOGRAPHY; HYBRID; HYDROLYSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHARMACOLOGY; PICTET SPENGLER REACTION; PRIORITY JOURNAL; STEREOCHEMISTRY; STRIATOPALLIDAL; THERAPY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; PEPTIDES; QUINOLIZIDINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 69749088827     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900149     Document Type: Article

References (36)

1. a) B. L. Roth, D. J. Sheffler, W. K. Kroeze, Nat. Rev. Drug Discovery 2004, 3, 353-359;
2. b) M. B. H. Youdim, J. J. Buccafusco, Trends Pharmacol. Sci. 2005, 26, 27-35.
3. For reviews, see: a) A. H. V. Schapira, E. Bezard, J. Brotchie, F. Calon, G. L. Collingridge, B. Ferrer, B. Hengerer, E. Hirsch, P. Jenner, N. Le Novère, J. A. Obeso, M. A. Schwarzschild, U. Spampinato, G. Davidai, Nat. Rev. Drug Discovery 2006, 5, 845-854;
4. b) K. Radad, G. Gille, W. D. Rausch, Pharmacol. Rep. 2005, 57, 701-712.
5. N. B. Mercuri, G. Bernardi, Trends Pharmacol. Sci. 2005, 26, 341-344.
6. a) C. R. Gerfen in The Rat Nervous System (Ed.: G. Paxinos), Elsevier, Amsterdam, 2004, pp. 445-508;
7. b) J. A. Obeso, M. C. Rodríguez-Oroz, B. Benitez-Temino, F. J. Blesa, J. Guridi, C. Marin, M. Rodriguez, Mov. Disord. 2008, 23, S548-S559.
8. M. Vendrell, E. Angulo, V. Casadó, C. Lluís, R. Franco, F. Albericio, M. Royo, J. Med. Chem. 2007, 50, 3062-3069.
9. B. Hoefgen, M. Decker, P. Mohr, A. M. Schramm, S. A. F. Rostom, H. El- Subbagh, P. M. Schweikert, D. R. Rudolf, M. U. Kassack, J. Lehmann, J. Med. Chem. 2006, 49, 760-769.
10. A. J. Bojarski, M. T. Cegla, S. Charakchieva-Minol, M. J. Mokrosz, M. Mackowiak, S. Misztal, L. J. Mokrosz, Pharmazie 1993, 48, 289-294.
11. Natural products themselves constitute a rich source of new hits and leads in medicinal chemistry. For example, see: a) R. Breinbauer, I. R. Vetter, H. Waldmann, Angew. Chem. 2002, 114, 3002-3015;
12. Angew. Chem. Int. Ed. 2002, 41, 2878-2890;
13. b) J. Y. Ortholand, A. Ganesan, Curr. Opin. Chem. Biol. 2004, 8, 271-280;
14. c) A. Ganesan, Curr. Opin. Chem. Biol. 2008, 12, 306-317.
15. E. Wenkert, P. D. R. Moeller, Y. J. Shi, J. Org. Chem. 1988, 53, 2383-2386, and references cited therein.
16. E. Wenkert, Acc. Chem. Res. 1968, 1, 78-81.
17. For the synthesis of 1,2-dihydropyridines, see: a) E. Wenkert, J. Wickberg, J. Am. Chem. Soc. 1965, 87, 1580-1589;
18. b) M. Lounasmaa, M. Puhakka, Acta Chem. Scand. Ser. B 1978, 32, 77-78;
19. c) M. Lounasmaa, M. Puhakka, Acta Chem. Scand. Ser. B 1978, 32, 216-220.
20. For the synthesis of 1,4-dihydropyridines, see: a) M. E. Brewster, A. Simay, K. Czako, D. Winwood, H. Farag, N. Bodor, J. Org. Chem. 1989, 54, 3721-3726.
21. For a recent review on the chemistry of dihydropyridines, see: b) R. Lavilla, J. Chem. Soc. Perkin Trans. 1 2002, 1141-1156.
22. For reviews, see: a) W. M. Whaley, T. R. Govindachari in Organic Reactions, Vol.6 (Ed.: R. Adams), Wiley, New York, 1951, pp. 151-190;
23. b) E. D. Cox, J. M. Cook, Chem. Rev. 1995, 95, 1797-1842.
24. For recent examples, see: a) N. Srinivasan, A. Ganesan, Chem. Commun. 2003, 916-917;
25. b) D. Bonnet, A. Ganesan, J. Comb. Chem. 2002, 4, 546-548;
26. c) J. D. Revell, N. Srinivasan, A. Ganesan, Synlett 2004, 1424-1430.
27. For reductions with NaBH3CN, see: a) U. Rosentreter, L. Born, J. Kurz, J. Org. Chem. 1986, 51, 1165-1171;
28. b) D. Spitzner, K. Arnold, J. J. Stezowski, T. Hildenbrand, S. Henkel, Chem. Ber. 1989, 122, 2027-2029.
29. For examples of enamine hydrogenations, see: R. Lavilla, O. Coll, J. Bosch, M. Orozco, F. J. Luque, Eur. J. Org. Chem. 2001, 3719-3729, and references cited therein.
30. The presence of a nitrogen atom at the β-position is thought to favor ester hydrolysis, probably through basic catalysis.
31. C. Missale, S. R. Nash, S. W. Robinson, M. Jaber, M. G. Caron, Physiol. Rev. 1998, 78, 189-225.
32. K. A. Neve, J. K. Seamans, H. Trantham-Davidson, J. Recept. Signal Transduction 2004, 24, 165-205.
33. V. Casadó, C. Cantí, J. Mallol, E. I. Canela, C. Lluís, R. Franco, J. Neurosci. Res. 1990, 26, 461-473.
34. S. Sarrió, V. Casadó, M. Escriche, F. Ciruela, J. Mallol, E. I. Canela, C. Lluís, R. Franco, Mol. Cell. Biol. 2000, 20, 5164-5174.
35. Y. C. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.
36. V. Casadó, T. Casillas, J. Mallol, E. I. Canela, C. Lluís, R. Franco, J. Neurochem. 1992, 59, 425-431.